The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Forty Seven's current ratio for the quarter that ended in Dec. 2019 was 14.81.
Forty Seven has a current ratio of 14.81. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Forty Seven's Current Ratio or its related term are showing as below:
FTSV's Current Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.775 * Ranked among companies with meaningful Current Ratio only.
Forty Seven Current Ratio Historical Data
The historical data trend for Forty Seven's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Forty Seven's Current Ratio
For the Biotechnology subindustry, Forty Seven's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Forty Seven's Current Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Forty Seven's Current Ratio distribution charts can be found below:
* The bar in red indicates where Forty Seven's Current Ratio falls into.
Forty Seven Current Ratio Calculation
The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.
Forty Seven's Current Ratio for the fiscal year that ended in Dec. 2019 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Forty Seven (NAS:FTSV) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Forty Seven Current Ratio Related Terms
Thank you for viewing the detailed overview of Forty Seven's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Forty Seven Inc is a clinical-stage immuno-oncology company. It is engaged in developing novel checkpoint therapies to activate macrophages and help the patients in their fight against cancer. It founded that blocking CD47, a key signaling molecule that is overexpressed on cancer cells renders tumors susceptible to macrophages. It is also preparing investigational compounds into clinical testing. FSI-174, an anti-cKIT antibody, is being developed in combination with magrolimab as a novel, all-antibody conditioning regimen to address the limitations of current stem cell transplantation conditioning regimens. FSI-189, an anti-SIRP-alpha antibody, is being developed for the treatment of cancer, and certain non-oncology conditions, including transplantation conditioning.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FTSV has been successfully added to your 